स्थानीय Piperān समाचार, भारत

Swirl Season To Debut Two Albums In All Stores This February

According to sources, Swirl Season’s “Wolfpack: No Taming (Vol. 001)” mixtape will debut on all platforms on February 3, 2021.

A second project will debut on February, 14, 2021. That project will be a re-release album titled “Romeo’s Dead” which will contain modifications of the original 2018 release.

How SA’s nascent vaccine industry can be developed - Business Day

If SA is serious about supplying anti-pandemic vaccines in the future, it needs to rethink the scale of financial, technical and strategic investment into vaccine production

The issue of vaccine production has become a topic of hot debate following the approval of treatments for COVID-19. In SA, angry exchanges have been spurred by the countrys lagging access to Covid-19 vaccines. Generally, vaccines are produced by private companies that sell the vaccine under contracts. In some cases, producers will make provisions for access in particular markets. This is sometimes as a condition for receiving early development funding or for allowing parts of production to occur in a particular country. Some middle-income countries, particularly India, Argentina and Mexico, have sufficient production capacity to be partly indispensable. These countries have strategic leverage to get vaccines because of their own vaccine manufacturing capacity. India illustrates this well. The Serum Institute of India (SII), a privately owned pharmaceutical company, is manufacturing large quantities of the University of Oxford/AstraZeneca and Novavax vaccines. The company is scheduled to reach 100-million doses produced a month by March 2021. In return, India will keep a portion of the vaccines it manufactures reportedly 100-million doses in the first instance. What about SAs own capacity to produce vaccines? What can the country do? SA does not have large-scale vaccine manufacturing capability. The Biovac Institute a public-private partnership between the government and a consortium of SA health-care companies is beginning to get into vaccine manufacture with an eye on more secure and accessible childhood vaccine supplies for Southern Africa. But this capability is still in its infancy. Its small compared to the Covid-19 vaccine market. In addition, a publicly traded SA-owned global pharmaceutical company, Aspen Pharmaceuticals, operates four pharmaceutical manufacturing and packaging plants in the country. The company is also moving into the vaccine packaging market. We see a clear disconnect between what would be needed to make Biovac a strategic vaccine asset and what is planned for Biovac. If SA is serious about supplying anti-pandemic vaccines in the future, it needs to rethink the scale of financial, technical and strategic investment into vaccine production. This investment must be made not only into the private sector, but also, critically, into publicly accountable institutions such as Biovac. Only if investment is increased, sustained, and backed by political commitment, will the country have sufficient vaccine production capacity to use as a lever to get national and regional access to future anti-pandemic vaccines. Vaccine production capacity Biovacs primary remit is to make childhood vaccines available for the Southern African market, mostly for the public sector. For its part, Aspens existing pharmaceutical manufacturing capacity is about 10-billion tablets a year. It produces generic drugs (including analgesics, a proton pump inhibitor and sleeping aids), nutritional supplements (notably iron supplements) and hormones for local African markets and other middle income markets, such as Turkey. Aspen is scheduled to start producing the Johnson & Johnson Covid-19 vaccine in March or April at these facilities. It will be filling and packaging vials with vaccine product manufactured in bulk outside SA. Most of the vials will be shipped back to J &J for international distribution. A recent announcement indicates that 9-million doses will remain in SA for local use. The original packaging deal between Aspen and J&J was announced more than two months prior. There had been no mention of a procurement deal for SA until pressure began to mount recently on all parties. Unlike Aspen, Biovacs remit is to provide vaccines in the public interest. Part of its mission is, to provide in the long term, capacity for the development and introduction of novel vaccines, focusing on the development of vaccines relevant to SA and Africas particular needs. Biovacs main activity is to import, label and distribute vaccines to the SA market. For example, it has supplied six vaccines made by international vaccine manufacturers for SAs childhood immunisation programme. It also supplies other countries in the region. Biovacs crowning achievement has been the local production (filling and packaging) of Hexaxim, a combination of six childhood vaccines from Sanofi, the French multinational pharmaceutical company. Production started very recently, in November 2020. Biovac is the first external company with which Sanofi has partnered to fill and package Hexaxim. Biovac is also planning to manufacture Prevnar 13, a vaccine made by Pfizer, the US multinational pharmaceutical company. The vaccine prevents pneumococcal disease and death. Biovac will formulate the product using components provided by Pfizer before filling and packaging the bulk vaccine. Production is due to start in the next six months. The development of local capacity for formulation of a complex vaccine marks another important step towards the establishment of vaccine manufacturing capacity in SA.

McGregor knocked out by Poirier in stunning UFC upset - Eyewitness News

The 32-year-old Poirier was ranked second in the flyweight division going into the fight, but still rated a heavy underdog by bookmakers to beat his fourth-ranked opponent, arguably the most famous fighter the sport has seen.

The 32-year-old Poirier was ranked second in the flyweight division going into the fight, but still rated a heavy underdog by bookmakers to beat his fourth-ranked opponent, arguably the most famous fighter the sport has seen. ABU DHABI - American underdog Dustin Poirier shook up the world of mixed martial arts Sunday, beating up the legs of Irish superstar Conor McGregor before knocking him out at UFC 257 in Abu Dhabi. "I'm happy but I'm not surprised. I put in the work," Poirier after the referee stepped in after 2min 32sec of the second round to save McGregor from further damage after he was dropped by a fierce combination of punches. The 32-year-old Poirier was ranked second in the flyweight division going into the fight, but still rated a heavy underdog by bookmakers to beat his fourth-ranked opponent, arguably the most famous fighter the sport has seen. The controversial McGregor, known as "Notorious", was returning to the octagon for the first time in a year and hoping for a repeat of the pair's first contest in 2014 which he won by TKO after just 109 seconds. But Poirier, who now has a UFC record of 27-6, used low calf kicks in an effort to put McGregor (22-5) off his usual ferocious stand-up game - and it worked. "First off I want to say Conor took this result professionally. We're 1-1 and maybe we're going to have to do it again," said Poirier, hinting at the prospect of a trilogy fight. "I'm happy with the place I am in. I'm happy with the face I see in the mirror. "The goal was to be technical and to pick my shots, not brawl at all. I had him hurt and I went a little crazy." McGregor likes to call himself "Mystic Mac" and had spent the week leading into the fight predicting he would end it inside 60 seconds. But it was a different Poirier to the one who had looked overmatched when the pair previously met at UFC 178 at the lighter featherweight. 'I'M GUTTED' Poirier worked the legs and took McGregor down into a grapple for much of the first round -- avoiding a boxing face-off against a man who once shared the ring with Floyd Mayweather and had touted a future fight against Manny Pacquiao. Poirier then found his range in the second, weakening McGregor's base with more calf kicks before exploding for the shock finish. He staggered McGregor with a big overhand left and then dropped him to the canvas with a straight right flush on the Irishman's nose before referee Herb Dean waved it off. "The low calf kick was very good but Dustin is some fighter," said McGregor. "I'll dust it off and come back because that's what I'll do. I'll take my licks. "I'm gutted, it's a tough one to swallow. I just want to go back to the hotel and chill with my kids and regroup." The second-ranked Poirier is now in prime position to either inherit or fight for the UFC's lightweight belt, most recently held by the now-retired unbeaten Russian Khabib Nurmagomedov. "I felt like this was the title fight. If Khabib's not coming back then I'm the champion," said Poirier. The fight was held inside the new Etihad Arena on the "Fight Island" bio-secure sporting hub of Yas Island that the Abu Dhabi government established last July. The three UFC events staged over the past week have been the first to allow fans to sit cageside, with around 2,000 in attendance for the main event. Download the Eyewitness News app to your iOS or Android device.